Russian pharmaceutical market: 2016 vs Anna Ermolaeva AlphaRM General Manager
|
|
|
- Eugenia Gibson
- 5 years ago
- Views:
Transcription
1 Russian pharmaceutical market: 2016 vs 2017 Anna Ermolaeva AlphaRM General Manager
2 Russian pharmaceutical market volume 16 ~1,13 (trln, RUB)* & ~5,3 (bln, units) Including Food Supplements (FS), Medical Devises (MD) and others ~1,4 trln, RUB and 7,7 billion, units 958 billion, RUB +11% +7% billion, units -4% 5,51-1% 5,29 5,26 69% 80% ,1-30% billion, USD 17,4-3% 16,8 1,084,43 1,05 4,24 1,02 4, ,9 billion, EUR -17% -3% 15,6 15,2 8,0 17,1 5,5 11,9 5,2 11, % 69% 6,1 12,8 5 10,7 4,7 10, Total market State segment Retail segment *Excluding Food Supplements (FS), Medical Devises (MD) and others Consumer price
3 Russian Pharmaceutical Market Structure 2016, national currency, consumer price Out-of-pocket money State budget RETAIL 68,8 % 13,0 % Reimbursement 13% 4% Retail 13,5 % Clinical segment 15% 68% 2015 Clinical segment Reimbursement Target segment 4,7 % Target segment State procurement *Excluding Food Supplements (FS), Medical Devises (MD) and others
4 EUR USD Units RUB Retail Pharmaceutical Market Started Growing In The Second Half of 16 Retail pharmaceutical market growth 2016 vs 2015 (%) 2016/2015: +9% -5% -2% -9% -3% +3% 0% +8% +23% +16% +15% +35% +7% -2% -12% -9% -16% -7% -7% -3% 0% +19% +13% +7% +25% 0% -9% -21% -16% -27% -25% -14% -11% +9% +27% +17% +16% +51% -2% -3% -19% -18% -31% -26% -15% -12% +8% +28% +19% +15% +56% -2% г г. (Sell-out)
5 There are more than 60 K pharmacies in Russia Segmentation by No. of pharmacies: 2015г. - 57,7 K Pharmacies + 4 % 2016г. - 60,2 K Pharmacies 17% 10% 17% 34% Local chains Small local chains Regional chains 22% Federal chains 18% 18% 13% 30% 21% Independent pharmacies Segmentation by revenue (sell-out), (%) RUB: 23% 13% 35% 24% 13% 30% 15% 14% 20% 13%
6 Dynamics of aggregate market shares among largest retailers Share of biggest players (by sales value, included in the TOP 100 pharmacy chains) is more than 50% of the retail commercial market. Consolidation continues , ,3 50, , , ,8 8,5 12,1 21,7 19,2 50, ,0 63,6 6,3 5,6 9,0 15,6 14,1 17,5 35,2 34,3 47,9 47,8 ТОР3 ТОР10 ТОР100 ТОР300 ТОР3 ТОР10 ТОР100 ТОР300 Share, RUR. RUB Share, pharmacies
7 TОР-20 Manufactures in the Retail Segment 16 (sell-out) Pharmstandart Sanofi Novartis Bayer Servier GSK Gedeon Richter STADA Berlin-Chemie Teva Abbott Johnson & Johnson Takeda KRKA Astellas Valenta Allergan Dr. Reddy's Pfizer Boehringer Ingelheim -10% 0% 10% 20% 30% Growth 2016/2015, RUB Share Corporation ( %, RUB) Pharmstandart 5,48% Sanofi 4,32% Novartis 4,04% Bayer 3,92% Servier 3,25% GSK 3,21% Gedeon Richter 2,91% STADA 2,83% Berlin-Chemie 2,81% Teva 2,69% Abbott 2,53% Johnson & Johnson 2,50% Takeda 2,21% KRKA 2,06% Astellas 1,92% Valenta 1,73% Allergan 1,69% Dr. Reddy's 1,68% Pfizer 1,49% Boehringer Ingelheim 1,37% 55%
8 Russian Pharmaceutical Retail Market includes > brands ТОР10 Brands Sales Growth (RUB) Share (RUB) Variation 2016 vs.2015 Cardiomagnyl 18,93% 0,82% +4 Kagocel 0,11% 0,77% 0 Theraflu 14,86% 0,74% +3 ~ 600 Brands account about 80% of sales Nurofen 5,53% 0,73% 0 Actovegin 1,60% 0,73% -2 Ingavirin 46,18% 0,72% +4 Essentiale N -16,11% 0,70% -6 Concor 9,23% 0,70% -1 Pentalgin 19,96% 0,69% 0 Detralex 35,28% 0,63% +6 Number of brands in the Russian market grew in 2016 by 5% to exceed items
9 Evalar - FS market leader Value of FS market 16 reached 43 bln. RUB, other product categories (MD, сosmetics and others) 213 bln. RUB billion, RUB. 6% % TOP10 FS MANUFACTURERS Value (bln, RUB) Share (RUB) Growth, 16/ 15, (%) Evalar 7,97 18,29% 13,33% Pharmstandart 2,40 5,50% 38,53% Pharmamed 2,20 5,05% -7,12% Valeant 1,96 3,84% -3,46% VIS 1,65 3,77% -50,60% Queisser 1,45 3,32% 5,44% Solgar 1,44 3,31% 37,96% Dr Reddy s 1,41 3,24% 18,58% Obnovlenie 0,92 2,11% 50,87% Polpharma 0,86 1,98% 13,33% MD+ FS
10 Structure of State Purchases (by auction date) Shared by purchase type (%) -12% 24,6 0, ,8 37,8-10% -9% % +40% 2014 г г г. Maximum Purchase Price, bln RUR. Final Purchase Price, bln RUR. Shared by funding source (%) 26,8 28,2 23,6 16,3 9,4 22,6 Clinical segment Reimbursment Rest (under 223-FL) Target Segment State Pharmacies (under 44-FL) Institutional Budget Regional Budget Federal Budget Fund of OMI Other Sources Shared by supplier selection type (%) 75,2 8,6 7,3 4,6 3,9 0,4 e-auction Single-Source Contract Quote Request RFP Open Auction Other
11 ТОР10 Suppliers of MS Tender Purchase (RUB, in bidding winner price) 16 Supplier Share (%) Value, RUB (mln) 1 R-Pharm 8, Pharmstandart 6, Pharmimex 3, Lancet 2, Pharmastor 2, Protek 2, Euroservice 1, Katren 1, Medipal-Onco 1, Irvin-2 1, ТОР10 33,
12 Clinical Segment Clinical Segment Dynamics, Bln. RUB Mln. Units 150,77 151,76 155,13 +1% +2% 858,08-5% 814,33-5% 772,
13 Recipients share (%) by type of medical institution in clinical segment 16 4,1 5,6 RUB (%) 2,0 0,3 3,7 4,7 Units (%) 2,9 0,2 88,0 88,5 Out-patient clinics Out-patient clinics (institutional) Hospitals Hospitals (institutional) Other purchases (under 223-FL)
14 TOP 10 Clinical Segment Manufactures 16 Rate Variation Manufacturer Value (bln, RUB) Volume (mln, units) Share (%, RUB) Growth, 16/ 15, (%) 1 8 Biocad 5,26 0,82 3, Roche 4,45 1,13 2, Sanofi 4,39 4,69 2, Pfizer 3,43 1,82 2, AstraZeneca 3,21 1,44 2, Bayer 2,93 1,39 1, Abbott 2,67 2,25 1, MSD 2,67 0,57 1, Novartis 2,66 0,62 1, Johnson & Johnson 2,27 0,73 1,47 12 TOP10 33,94 15,46 21,71
15 Dynamics of reimbursement segment, RUB, (bln) Units, (mln) 117,6 +18,2% 139,1 +3,7% 144,2 108,2 +18,3% 128,0 +1% 129,4 52,3 75,0 2,1 45,7 79,3 3,0 51,6 52,3 4,3 60,2 45,0 39,1 54,3 40,7 44,1 40,9 32,4 44, Overall Reimbursement High Cost Nosologies Federal Reimbursement Regional Reimbursment
16 Dynamics of Reimbursement Share (%) by localization High cost nosologies Regional Reimbursement 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 31,7 64,6 Локальные Local Импортные Import 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 15,4 25,3 0% 2015 г г. 0% Federal Reimbursement 2015 г г. 100% 80% 28,3 37,2 60% 40% 20% RUB 0% 2015 г г.
17 Rate Variation ТОР10 Manufacturers in Reimbursement Segment 16 (RUB) Manufacturer Value (bln, RUB) Volume (mln, units) Share (%) Growth 16/ 15, (%) 1 9 Nativa 10,23 1,67 7, Celgene 9,86 0,03 6, Sanofi 7,72 4,04 5, Biocad 7,58 0,47 5, Roche 6,72 0,68 4, Novo Nordisk 6,08 3,46 4, AstraZeneca 5,52 1,84 3, Novartis 5,36 1,69 3, Johnson & Johnson 5,24 0,51 3, Alexion 4,27 0,01 2,96-17 ТОР10 68,58 14,4 47,55
18 Rate Variation ТОР10 Brands in Reimbursement Segment 16 Brand Manufacturer Value (bln, RUB) Volume (mln, units) Share (%) 1 - Revlimid Celgene 9,42 0,02 6, Lantus Sanofi 4,49 1,36 3,11 - Growth (%) 3 - Soliris Alexion 4,27 0,01 2, new Aksoglatitan FS Nativa 3,92 0,19 2,72 new 5 1 Boramilan Nativa 3,25 0,10 2, Acellbija Biocad 2,71 0,66 1, Symbicort AstraZeneca 2,04 1,06 1, Levemir Novo Nordisk 2,01 0,82 1, Remicade MSD 1,84 0,04 1, Novorapid Novo Nordisk 1,83 1,07 1,26 26 ТОР10 35,78 5,33 24,79
19 Dynamics of Target Segment RUB, (bln.) Units (mln.) 38,6 +19% 46,1 +15% 52,4-4% 107,1 103,2 +10% 113,7 19,5 27,7 11,4 8,6 11,6 8,2 7,7 5,8 0,6 1,5 1,4 0,4 0,9 0, ,1 Overall Segment Regional Dedicated Programmes Federal Dedicated Programmes 51,5 56,1 48,1 41,4 23,9 25,0 20,4 9,1 9,6 11,0 11,0 11,1 2,2 2,1 1, Maternity Certificate Federal Penal Correction Service Other
20 ТОР10 Manufactures in Target Segment 16 Rate Variation Manufacturer Value (bln, RUB) Volume (mln, units) Share (%) Growth (%) 1 - AbbVie 6,74 0,83 12, Pharmasyntez 4,61 4,75 8, Pfizer 4,56 3,60 8, Microgen 2,96 10,54 5, Bristol-Myers Squibb 2,33 0,32 4, MSD 2,21 0,22 4, Johnson & Johnson 2,03 0,20 3, Petrovax 1,96 8,33 3, ViiV 1,42 0,36 2, Biocad 0,89 0,46 1, ТОР10 29,71 29,61 55,79
21 ТОР10 Brand in Target Segment 16 Rate Variation Brand Manufacturer Value (bln, RUB) Volume (mln, units) Share (%) Growth (%) 1 - Kaletra AbbVie 5,79 0,80 10, Prevenar Pfizer 4,27 3,48 8, Isentress MSD 2,00 0,15 3, Grippol Petrovax Pharm 1,94 8,27 3, Sovigripp Microgen 1,79 7,94 3, Reyataz Bristol-Myers Squibb 1,77 0,23 3, Intelence Johnson & Johnson 1,42 0,13 2, Kemeruvir Pharmasyntez 1,32 0,07 2, Olitid Pharmasyntez 0,80 0,28 1, Kivexa ViiV 0,68 0,15 1,29-27 ТОР10 21,78 21,5 41,14
22 Pharmaceutical Market. Key Trends 17 Retail Consolidation 16/ 15: Federal & Regional Pharmacy Chains share + 8% Retention of Health Care Financing 17/ 16: +5,9% Shift of State Pharmacy Chains to 44-FL Purchase 6 K Pharmaсies New Pharmacy sales channel remote pharmaceuticals sales «Reference price» System QR-coding Pilot Project
23 Pharmaceutical market growth, Q1 16 vs Q1 17 total market growth is 10% (RUB), MAT vs MAT is 10% Retail segment +16% +13% +11% Billion, RUB Q1 17/ Q % MAT 03 16/ MAT % 50 State segment Q1 17/ Q1 16-3% % -3% Billion, RUB -28% MAT 03 16/ MAT %
24 % Pharmaceutical Market Growth in RUB Retail segment is expected to grow by more than 12%, Pharmaceutical market growth will significantly exceed official inflation rate % % % Billion, RUB * State segment Retail segment
25 THANK YOU FOR YOUR ATTENTION alphapharm.ru Vavilova Str., 1, Moscow, Russia г. Москва, ул. Вавилова, д.1
Overview of the retail commercial segment of pharmaceutical dietary supplements market in 2016
Overview of the retail commercial segment of pharmaceutical dietary supplements market in 2016 The capacity of the commercial segment of the pharmaceutical market (medicinal products, dietary supplements,
Overview of the retail commercial segment of the pharmacy market for dietary supplements based on the results of the 1 st half of 2017
Overview of the retail commercial segment of the pharmacy market for dietary supplements based on the results of the 1 st half of 2017 The capacity of the commercial segment of dietary supplements reached
Pharmacy sales, $ mil. (wholesale prices) Decem- Growth gain, % (roubles) Region. December. January 18 December. January
MACROECONOMIC INDICES Inflation According to Federal State Statistics Service s data, the Consumer Price Index was estimated as 1.2% in February 218, compared to the previous month, 1.5% as against December
OTCPharm FY/Q sales results
OTCPharm FY/Q4 2014 sales results Olga Mednikova, CEO Irina Bakhturina, Head of Investor Relations February, 2015 Russia Pharma Market Update In 2014, Russian commercial OTC market grew by 9.5% y-o-y reaching
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group MACROECONOMIC INDICES Inflation According to Federal State Statistics Service s data, in
OTCPharm H1/Q2 sales results
OTCPharm H1/Q2 sales results Olga Mednikova, CEO Irina Bakhturina, Head of Investor Relations August, 2014 5 Jul 2013 Pharmstandard BoD convened two Extraordinary Shareholders Meetings ( ESMs ) on spin-off
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
AIPM - Remedium Market Bulletin, page 2 Issue 1, January 2015
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group MACROECONOMIC INDICES Inflation Table 1. Top ten chemical and pharmaceutical manufacturers
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group
Indices (to October 213) Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group MACROECONOMIC INDICES Inflation Table 1. Top ten chemical and pharmaceutical
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES
Indices (to April ) ) A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Manufacturer Inflation According
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
MACROECONOMIC INDICES Inflation
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Inflation The Top-1 domestic manufacturers by production
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group MACROECONOMIC INDICES Inflation According to Federal State Statistics Service s data, in
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
Table 1. Top-ten chemical and pharmaceutical manufacturers by production volume in September 2012 Inflation
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Table 1. Top-ten chemical and pharmaceutical manufacturers
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group
Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Remedium Group MACROECONOMIC INDICES Inflation Table 1. Top ten chemical and pharmaceutical manufacturers
MACROECONOMIC INDICES Inflation. Domestic production are shown in Table 1. The total production volume by top ten
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Inflation Domestic production According to Federal State
MACROECONOMIC INDICES Inflation
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Inflation The top 1 domestic manufacturers by production
MACROECONOMIC INDICES Inflation
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Inflation Table 1. Top-ten chemical and pharmaceutical
Dear colleagues! The year 2006 opened new possibilities. The key question of 2007 is to use them. Good luck to all of you!
Dear colleagues! I would like to tell a few words about Russian pharmaceutical market in 2006. The tendency is that the Word of Three Letters gained in great importance. Firstly, it is of course the magic
PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars
PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse
HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Inflation According to Federal State Statistics Service
taking at (Jan. 21, 2016) by Older 2016.pdf).
HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES
A Joint Publication of the Association of International Pharmaceutical Manufacturers in Russia and Group of Companies Remedium MACROECONOMIC INDICES Manufacturer Inflation position According to Federal
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
NATIVA GROUP. Inspired by Innovation and Technology
NATIVA GROUP Inspired by Innovation and Technology INNOVATION & TECHNOLOGY IS OUR PASSION Nativa is a leading group of pharmaceutical companies in Russia. It develops and produces worldclass complex medicines
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research
Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research The global visceral pain market size was estimated at USD 9.51 billion in 2016 and is expected to
2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
This is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it s Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market
Custom Intelligence. Alzheimer s Disease Landscape Summary
Custom Intelligence Alzheimer s Disease Landscape Summary Prepared August 21 Alzheimer s Disease Landscape: Executive Summary Current standard of care in Alzheimer s Disease (AD) consists of symptomatic
(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
China Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011
China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device
Q Update Tracking the Effect of the Economic Crisis on Pharmaceutical Consumption, Expenditures
Q4 2009 Update Tracking the Effect of the Economic Crisis on Pharmaceutical Consumption, Expenditures and Unit Prices Executive Summary The WHO, in collaboration with IMS, has put in place a programme
Investor Update May 2016
Investor Update May 2016 Novo Nordisk poised for growth through helping care for rising global diabetes epidemic On Marsico Capital Management s trip to Australia in March, Portfolio Managers Tom Marsico
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)
DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p
Post Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
Boston University Expert Review Meeting on the Evaluation of Novartis Access
Boston University Expert Review Meeting on the Evaluation of Novartis Access Principal Investigator: Richard Laing Co-investigators: Peter Rockers, Veronika Wirtz, Taryn Vian, Monica Onyango, Paul Ashigbie
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global
COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and
Vascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors
TABLE OF CONTENTS CHAPTER ONE: EXECUTIVE SUMMARY Scope and Methodology Size and Growth of the Market Issues and Trends Affecting the Rx-to-OTC Switches Market Leading Competitors CHAPTER TWO: INTRODUCTION
Exhibitor Prospectus
+ National Meeting and Expo 2018 Exhibitor Prospectus The 2018 Innovatix + Essensa National Meeting & Expo is the only event that provides access to Innovatix and Essensa s most engaged and active members,
SUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
Oncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
An exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
United States Tuberculosis Vaccine Industry 2016 Market Research Report
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > United States Tuberculosis Vaccine Industry 2016 Market Research Report United States Tuberculosis Vaccine Industry
TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE
TRENDS IN MANUFACTURER PRICES OF BRAND-NAME PRESCRIPTION DRUGS USED BY OLDER AMERICANS SECOND QUARTER 2006 UPDATE INTRODUCTION This Data Digest reports on changes in manufacturer prescription drug prices
A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
Health for Humanity 2020 Goals 2
2017 for Humanity Report Better for Humanity 2020 s 2 At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our for Humanity 2020 s, underpinned by 16 targets, focus
Case No COMP/M BRISTOL MYERS SQUIBB / DU PONT. REGULATION (EEC) No 4064/89 MERGER PROCEDURE. Article 6(1)(b) NON-OPPOSITION Date: 09/08/2001
EN Case No COMP/M.2517 - BRISTOL MYERS SQUIBB / DU PONT Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 09/08/2001 Also
Current and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
No.Ayur-Ja (7)-1/97-III Dated, Shimla-2, the NOTIFICATION. In supersession of this Department s Office Order of even number
Government of Himachal Pradesh Department of Ayurveda No.Ayur-Ja (7)-1/97-III Dated, Shimla-2, the 31-8-2009 NOTIFICATION In supersession of this Department s Office Order of even number dated 5 th February,
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES
GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS
ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
Insights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
Prescription Drugs. Medicare & Medicaid Briefings National Health Policy Forum February 22, Jim Hahn Congressional Research Service
Prescription Drugs Medicare & Medicaid Briefings National Health Policy Forum February 22, 2007 Jim Hahn Congressional Research Service Global and US. Prescription Drug Sales, 1998-2005 $700 $600 559 602
Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS
GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS
INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA
MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
I n t r o d u c t i o n t o t h e P h a r m a c e u t i c a l I n d u s t r y
I n t r o d u c t i o n t o t h e P h a r m a c e u t i c a l I n d u s t r y U n i v e r s i t y J o i n s I n d u s t r y M a r c h 1 5, 2 0 1 7 J a v i e r T o r r e j ó n Topics to be covered today..
Operational Efficiency:
Operational Efficiency: metrics that matter Copyright Altus Ltd 214. All rights reserved. Kevin Okell Consultancy Director 15/5/214 From distribution chain to value chain Ad-valorem pricing driven from
SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB
Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon),
U.S. Insomnia Market by Non-Pharmacological Therapy (CBTI, Hypnotherapy), Prescription Sleep Aids (Benzodiazepines, Non-Benzodiazepines (Zaleplon), Orexin Antagonist) & OTC Treatment (Antihistamine, Melatonin,
Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
Influenza Vaccination Market Research Report Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR
Adherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA
Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research
Pharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
China Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
The Data Collection on Adverse events of Anti-HIV Drugs
Dias 1 The Data Collection on Adverse events of Anti-HIV Drugs Ole Kirk, University of Copenhagen Denmark Dias 2 The Need for D:A:D February 1999, EMEA/Committee for Medicinal Products for Human Use (CHMP)
Tamper-Resistant Properties of Drugs Regulations (TRPDR)
Tamper-Resistant Properties of Drugs Regulations (TRPDR) Cost Impact Analysis, 2019 PMPRB presentation to federal, provincial, and territorial public plan representatives on September 29, 2015. 1 Patented
SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
Blood Glucose Test Strip Market Research Report- Global Forecast till 2020
Report Information More information from: https://www.marketresearchfuture.com/reports/976 Blood Glucose Test Strip Market Research Report- Global Forecast till 2020 Report / Search Code: MRFR/MED/0470-CRR
Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology
Market Distortions from the 340B Drug Pricing Program
Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect
Why GAVI Needs to Do More To Ensure Lower Vaccine Prices And How It Could Be Done
Why GAVI Needs to Do More To Ensure Lower Vaccine Prices And How It Could Be Done Vaccines are widely considered a highly cost-effective public health intervention. Médecins Sans Frontières (MSF) is actively
Recommended comparator products: Medicines for HIV/AIDS and related diseases
Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal
Approval for Manufacturing and Marketing of Micatrio
Press Release September 28, 2016 Nippon Boehringer Ingelheim Co., Ltd. Astellas Pharma Inc. Approval for Manufacturing and Marketing of Micatrio Combination Tablets, an Antihypertensive Drug Japan s first
Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study
Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study Presented By: Scott McKibbin Special Advocate For Prescription Drugs State Of Illinois
Karan Sharma. Phone: Availability: Fulltime. 4:00 AM to 9:00 PM (GMT) Language groups:
Karan Sharma Phone: +91 7696 060 123 Email: karansharma008@yahoo.co.in Availability: Fulltime 4:00 AM to 9:00 PM (GMT) Language groups: EnglishHindi EnglishPunjabi Skills: Translation Proofreading/Editing
Global Vitamin Market Professional Survey Report 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Vitamin Market Professional Survey Report 2016 Global Vitamin Market Professional Survey Report 2016 Publication
STARCH AND RUSSIAN MARKET OF STARCH
STARCH AND RUSSIAN MARKET OF STARCH MOSCOW 2012 1 CONTENTS LIST OF CONTENTS... 3 RESEARCH METHODOLOGY... 5 EXTRACTS FROM RESEARCH... 6 LIST OF SCHEDULES, DIAGRAMS, TABLES AND SCHEMES... 9 ABOUT INTESCO
This article is a CME/CE certified activity. To earn credit for this activity visit:
Novel Perspectives on Type 2 Diabetes: Traditional and Emerging Therapies and the Potential Role of the Kidneys This article is a CME/CE certified activity. To earn credit for this activity visit: www.medscape.org/lecture/t2dm-therapies
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
HALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles
Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,
APPENDIX A: Tobacco Marketing Expenditure Categories
APPENDIX A: Tobacco Marketing Expenditure Categories The Federal Trade Commission (FTC) issues reports on annual cigarette and smokeless tobacco marketing expenditures, which are based on data from the
Vaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
Quality Medical Donations
PQMD members played an active role in relief efforts following devastating floods left by Hurricane s Harvey, Irma, and Maria. PQMD Community of Practice: Connect Convene - Catalyze Are you an engaged
Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators
Exhibitor Name Booth Number Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators 358 Accredo 947 Adako 276
Case No COMP/M ABBVIE/ SHIRE. REGULATION (EC) No 139/2004 MERGER PROCEDURE. Article 6(1)(b) NON-OPPOSITION Date: 16/10/2014
EN Case No COMP/M.7339 - ABBVIE/ SHIRE Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 16/10/2014 In electronic form
SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84
CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:
CANNABIS MANAGEMENT CORPORATION REGULATIONS
c t CANNABIS MANAGEMENT CORPORATION REGULATIONS PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this regulation, current to August 11, 2018. It is intended
Novo-Nordisk As (NVO-NYSE) Analyst Note
February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00